Is plasminogen activator inhibitor-1 a physiological bottleneck bridging major depressive disorder and cardiovascular disease?

Acta Physiologica
C SavoyMeir Steiner


Major depressive disorder (MDD) is estimated to affect one in twenty people worldwide. MDD is highly comorbid with cardiovascular disease (CVD), itself one of the single largest causes of mortality worldwide. A number of pathological changes observed in MDD are believed to contribute to the development of cardiovascular disease, although no single mechanism has been identified. There are also no biological markers capable of predicting the future risk of developing heart disease in depressed individuals. Plasminogen activator inhibitor-1 (PAI-1) is a prothrombotic plasma protein secreted by endothelial tissue and has long been implicated in CVD. An expanding body of literature has recently implicated it in the pathogenesis of major depressive disorder as well. In this study, we review candidate pathways implicating MDD in CVD and consider how PAI-1 might act as a mediator by which MDD induces CVD development: chiefly through sleep disruption, adiposity, brain-derived neurotrophic factor (BDNF) metabolism, systemic inflammation and hypothalamic-pituitary-adrenal (HPA)-axis dysregulation. As both MDD and CVD are more prevalent in women than in men, and incidence of either condition is dramatically increased during reproductive mi...Continue Reading


Aug 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·J SchneidermanDavid J Loskutoff
Jan 1, 1989·American Journal of Obstetrics and Gynecology·K de BoerP E Treffers
Apr 25, 1970·British Medical Journal·J BonnarA S Douglas
Mar 14, 1995·Proceedings of the National Academy of Sciences of the United States of America·P ErikssonA Hamsten
Jan 1, 2000·Journal of Psychosomatic Research·S SchwartzD Blazer
Mar 4, 2000·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·R R De Marco
Mar 10, 2000·Cytokine & Growth Factor Reviews·T A McCaffrey
Jan 17, 2002·Proceedings of the National Academy of Sciences of the United States of America·Koji YamamotoHidehiko Saito
Apr 3, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Lucile CapuronAndrew H Miller
Apr 5, 2002·Neuron·Eric J NestlerLisa M Monteggia
Jun 4, 2002·The American Journal of Psychiatry·Brett Silverstein
Jan 14, 2003·Nature Neuroscience·Robert PawlakSidney Strickland
Jan 18, 2003·Sleep Medicine Reviews·Maurice M Ohayon
Sep 19, 2003·Biochemical and Biophysical Research Communications·Zongpei JiangHi B Lee
Nov 4, 2004·Biological Psychiatry·Craig A StockmeierGrazyna Rajkowska
Feb 25, 2005·The Journal of Clinical Endocrinology and Metabolism·Theresa M Buckley, Alan F Schatzberg
Apr 21, 2005·Thrombosis and Haemostasis·Jerry P Melchor, Sidney Strickland
Jul 1, 2005·Metabolism: Clinical and Experimental·Farideh EskandariPOWER (Premenopausal, Odteopenia/Osteoporosis, Women, Alendronate, Depression) Study Group
Aug 4, 2005·Atherosclerosis·Athanassios D DoulalasDimitrios T Kremastinos
Aug 17, 2005·Journal of Thrombosis and Haemostasis : JTH·Douglas E Vaughan
Jan 21, 2006·Hippocampus·Jennifer L Warner-Schmidt, Ronald S Duman
Apr 14, 2006·Current Vascular Pharmacology·Suzanne M NichollMark G Davies
Jul 28, 2006·Journal of Psychiatric Research·Sinead M O'BrienTimothy G Dinan
Jan 4, 2008·The New England Journal of Medicine·R H Belmaker, Galila Agam
Jan 24, 2008·Circulation·Ralph B D'AgostinoWilliam B Kannel
Apr 25, 2008·The New England Journal of Medicine·Andrea SainiAlfredo Berruti
Aug 5, 2008·Trends in Neurosciences·Carmine M Pariante, Stafford L Lightman
Aug 22, 2008·Psychotherapy and Psychosomatics·Franziska GeiserUrsula Harbrecht
Aug 30, 2008·The International Journal of Neuropsychopharmacology·André Russowsky BrunoniFelipe Fregni
Dec 27, 2008·Progress in Cardiovascular Diseases·Janet M MullingtonHans K Meier-Ewert
Mar 27, 2009·Nature Reviews. Nephrology·Hunjoo HaHi B Lee
Apr 18, 2009·Harvard Review of Psychiatry·Jennifer L PayneHadine Joffe
Aug 21, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Joseph L Price, Wayne C Drevets
Jul 6, 2010·Lancet·Eric A P SteegersRobert Pijnenborg
Jan 6, 2011·Expert Opinion on Therapeutic Targets·Md Shenuarin Bhuiyan, Kohji Fukunaga
Jan 22, 2011·Psychiatry Investigation·Bun-Hee Lee, Yong-Ku Kim
Feb 9, 2011·Journal of Affective Disorders·Chiara BaglioniDieter Riemann
Apr 6, 2011·Journal of Cellular Physiology·Asish K Ghosh, Douglas E Vaughan
Jun 3, 2011·The New England Journal of Medicine·Lawrence R Wechsler
Aug 2, 2011·Seminars in Thrombosis and Hemostasis·Jodi A LeeMarie Ranson
Aug 3, 2011·Irish Journal of Medical Science·H ChenJ Zhang
Jan 6, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Kevin G BathIpe Ninan
Jun 27, 2012·Nature Reviews. Cardiology·Charles B Nemeroff, Pascal J Goldschmidt-Clermont
Sep 18, 2012·Journal of Psychosomatic Research·Misty A W Hawkins, Jesse C Stewart
Oct 9, 2012·Science·Ronald S Duman, George K Aghajanian
Feb 13, 2013·Molecular Psychiatry·M GieseA Eckert
Mar 22, 2013·Annual Review of Public Health·Ronald C Kessler, Evelyn J Bromet
Apr 30, 2013·Progress in Cardiovascular Diseases·Larkin Elderon, Mary A Whooley
Aug 6, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Antti-Pekka ElomaaSoili M Lehto
Nov 10, 2013·BMJ : British Medical Journal·Alyshah Abdul SultanMatthew J Grainge
Nov 28, 2013·European Heart Journal·David L HareTiny Jaarsma
Feb 11, 2014·Therapeutic Advances in Cardiovascular Disease·Lauren WrightMeir Steiner
Jul 22, 2014·Diabetes & Metabolic Syndrome·Ashok Kumar AhirwarJayashree Bhatacharjee
Aug 13, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Emily G JacobsJill M Goldstein
Aug 17, 2014·Journal of Affective Disorders·Juan Joseph YoungNunzio Pomara
Sep 17, 2014·Frontiers in Psychology·Minati Singh
Oct 14, 2014·Frontiers in Cellular and Infection Microbiology·Torsten G LoofEva Medina
Nov 12, 2014·TheScientificWorldJournal·Songul Yasar YildizMehmet Agirbasli
Dec 3, 2014·Physiology & Behavior·Mimi TangLihong Zhang
Jan 31, 2015·Thrombosis Journal·Elena N Lipets, Fazoil I Ataullakhanov
Sep 26, 2015·Birth Defects Research. Part C, Embryo Today : Reviews·Leonid A ParunovIlya I Serebriyskiy
Oct 27, 2015·Frontiers in Cellular Neuroscience·Samuel D RobinsonNigel P Birch
Nov 4, 2015·Frontiers in Cellular Neuroscience·Arnaud ChevilleyDenis Vivien
Jan 16, 2016·Current Neuropharmacology·Frank M SchmidtNicole Lichtblau
Jan 20, 2016·Genetics and Molecular Research : GMR·L L ZhangY Kui
Feb 3, 2016·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Mario Maj
Dec 15, 2016·Magnesium Research : Official Organ of the International Society for the Development of Research on Magnesium·Wiesław Jerzy CubałaBartosz Wielgomas


Jan 18, 2018·Acta Physiologica·P B Persson, A Bondke Persson
Jun 3, 2017·Arteriosclerosis, Thrombosis, and Vascular Biology·Douglas E VaughanAsish K Ghosh
May 31, 2019·Therapeutic Advances in Cardiovascular Disease·Gabriella F MattinaMeir Steiner

Related Concepts

Cardiovascular Diseases
Involutional Paraphrenia
Plasminogen Activator Inhibitor 1
Biological Markers
Cardiovascular Diseases
Mental Depression
Heart Diseases

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.